US Hereditary Angioedema Therapeutics Market Research Report: By Type (Type I, Type II), By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others), By Treatment (Prophylaxis - Long-term Prophylaxis, Short-term Prophylaxis, On-demand), By Route of Administration (Intravenous, Subcutaneous, Oral) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Forecast to 2035

US Hereditary Angioedema Therapeutics Market Overview:

As per MRFR analysis, the US Hereditary Angioedema Therapeutics Market Size was estimated at 1.43 (USD Billion) in 2023. The US Hereditary Angioedema Therapeutics Market Industry is expected to grow from 1.65(USD Billion) in 2024 to 9.13 (USD Billion) by 2035. The US Hereditary Angioedema Therapeutics Market CAGR (growth rate) is expected to be around 16.827% during the forecast period (2025 - 2035).

Key US Hereditary Angioedema Therapeutics Market Trends Highlighted

The US Hereditary Angioedema (HAE) Therapeutics Market is currently witnessing notable trends driven by an increasing awareness of HAE and a rise in the diagnosis of this rare condition. Key market drivers include the availability of new and advanced treatment options, such as C1-esterase inhibitor therapies and bradykinin receptor antagonists, which have significantly improved patient outcomes. Additionally, the emphasis on personalized medicine is helping tailor treatments to individual patient needs, enhancing overall therapeutic efficacy. Opportunities in this market are expanding as healthcare providers and pharmaceutical companies focus on developing innovative therapies exceeding current treatment capabilities.The growing population of patients diagnosed with HAE in the US, which is estimated to be around 6,000 to 10,000 individuals, presents untapped potential for new drug development and therapies. There is also an increasing participation in clinical trials aimed at finding new treatments, which can provide patients with access to cutting-edge therapies while also advancing knowledge in this area. Recent trends indicate that patient advocacy groups are playing a significant role in raising awareness and improving access to treatments. The collaboration between these groups and healthcare professionals is helping facilitate the understanding of HAE’s impact and promote timely diagnosis.Furthermore, the US Food and Drug Administration's push for expedited drug approval processes is enabling quicker access to innovative therapies for patients, showcasing the commitment to enhancing care standards in the realm of hereditary angioedema treatment.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Hereditary Angioedema Therapeutics Market Drivers

Increasing Awareness and Diagnosis of Hereditary Angioedema

In the United States, the awareness and understanding of Hereditary Angioedema (HAE) have significantly improved over the past decade. The creation of awareness campaigns by organizations such as the US Hereditary Angioedema Association and the National Institutes of Health has led to better recognition of symptoms and conditions associated with HAE. According to the Health Resources and Services Administration, approximately 1 in 50,000 individuals in the US are diagnosed with HAE, up from historical estimates of 1 in 150,000.This increase in diagnosed cases is driving the demand for therapeutics and creating a growing US Hereditary Angioedema Therapeutics Market Industry, as more patients seek effective treatment options and management strategies. With more healthcare practitioners educated on the condition, early diagnosis can lead to timely interventions, reduced emergency room visits, and improved patient outcomes, further expanding the market.

Advancements in Therapeutics and Treatment Options

The US Hereditary Angioedema Therapeutics Market Industry is experiencing substantial growth primarily due to the advancements in therapeutics and the introduction of novel treatment options. The last few years have seen new drugs, such as C1 Inhibitors and bradykinin inhibitors, receiving approval from the U.S. Food and Drug Administration. Currently, nearly eight different products are approved specifically for treating HAE in the US, providing tailored treatment approaches for diverse patient needs.Moreover, ongoing Research and Development conducted by major pharmaceutical companies, including Shire and CSL Behring, has reported a remarkable increase in treatment outcomes, with some therapies showing over 75% efficacy in reducing HAE attacks. This continued innovation is expected to propel market growth and increase accessibility to effective treatments across various demographics.

Growing Patient Population and Prevalence of HAE

The US Hereditary Angioedema Therapeutics Market Industry is also benefiting from a growing patient population suffering from HAE. The U.S. Census Bureau indicates that the population in the US is expected to exceed 350 million by 2030, with an increasing proportion of individuals at risk for HAE. A study published in the Journal of Allergy and Clinical Immunology estimates that the prevalence of HAE may rise by up to 20% in the coming decade due to improved genetic testing methods.As more people become aware of their genetic predisposition, the market demand for effective therapeutics is anticipated to rise sharply. This growing patient base will not only present opportunities for existing companies but will also attract new entrants into the US Hereditary Angioedema Therapeutics Market Industry.

US Hereditary Angioedema Therapeutics Market Segment Insights:

Hereditary Angioedema Therapeutics Market Type Insights

The Type segment of the US Hereditary Angioedema Therapeutics Market is crucial in understanding the landscape of treatments available for this rare genetic disorder. The market is primarily categorized into Type I and Type II, each with unique characteristics and treatment requirements. Type I is characterized by a deficiency of the C1 esterase inhibitor, which leads to uncontrolled inflammation and swelling; hence, the demand for effective therapies has surged in recent years. This type accounts for the majority of hereditary angioedema cases in the US, making it a significant focus for research and therapeutic developments. Patients often require on-demand treatment during acute attacks, which has spurred innovation in targeted therapies and the emergence of novel medications tailored specifically for this group.On the other hand, Type II, although less common, is marked by the presence of dysfunctional C1 inhibitors, which can also lead to life-threatening episodes of swelling. The pathophysiology of Type II is similar to Type I, but the management strategies may differ, creating a distinct avenue for therapeutic options and challenges in care. Both types present unique treatment paradigms and influence the US Hereditary Angioedema Therapeutics Market dynamics substantially. The increase in awareness and diagnosis of hereditary angioedema has improved patient outcomes, prompting more investment in Research and Development to explore potential biological therapies and genetic editing technologies.Overall, the Type segment represents a vital component of the US Hereditary Angioedema Therapeutics Market, reflecting the complexity of the condition and the ongoing need for effective management strategies. The growing patient population and advancements in understanding the genetic basis of these disorders fuel demand for innovative solutions. As healthcare providers continue to recognize the varied presentations and treatment needs of Type I and Type II, the market is expected to evolve accordingly, aligning with emerging trends in precision medicine and personalized therapeutic approaches. The emphasis on patient-centered care will likely enhance therapeutic adherence, leading to better disease management and quality of life for individuals living with hereditary angioedema.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Hereditary Angioedema Therapeutics Market Drug Class Insights

The US Hereditary Angioedema Therapeutics Market within the Drug Class segment is witnessing significant attention from stakeholders, driven by the increasing prevalence of hereditary angioedema (HAE) and the growing demand for effective treatments. The segmentation includes various components such as C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others. C1 Esterase Inhibitors are crucial as they directly address the deficiency in patients and have historically been a standard of care, significantly contributing to improving patient outcomes.Selective Bradykinin B2 Receptor Antagonists are gaining traction due to their innovative approach in managing angioedema episodes, providing an essential alternative to traditional therapies. Kallikrein Inhibitors represent a newer class, showing promise in reducing the frequency and severity of HAE attacks, reflecting ongoing advancements in Research and Development within the industry. Others in this market category include a range of products that utilize different mechanisms of action to ensure effective management, appealing to a broader patient demographic.Overall, the growth of the US Hereditary Angioedema Therapeutics Market segmentation reflects a trend toward more personalized and effective treatment options for patients suffering from this condition.

Hereditary Angioedema Therapeutics Market Treatment Insights

The Treatment segment of the US Hereditary Angioedema Therapeutics Market plays a crucial role in managing this rare genetic condition characterized by recurrent episodes of severe swelling. Within this segment, Prophylaxis is a vital approach used to prevent attacks, and it includes Long-term Prophylaxis, Short-term Prophylaxis, and On-demand therapies. Long-term Prophylaxis is particularly significant as it helps to minimize the frequency and severity of attacks, which can greatly enhance the quality of life for patients. Short-term Prophylaxis is employed in specific situations, such as before surgical procedures or potential triggers, allowing patients to manage risks effectively.On-demand therapies are designed for immediate relief during acute episodes, emphasizing the need for rapid action to alleviate symptoms. The dominance of these approaches is driven by the rising awareness of hereditary angioedema among healthcare professionals and patients alike, along with advancements in treatment modalities. The US market continues to provide opportunities for innovation in treatment strategies, which is essential for meeting the needs of individuals affected by this complex condition. Overall, the segmentation within the Treatment segment underscores the diverse yet complementary strategies required to tackle hereditary angioedema effectively in the US.

Hereditary Angioedema Therapeutics Market Route of Administration Insights

The Route of Administration segment in the US Hereditary Angioedema Therapeutics Market is crucial for determining how therapies are delivered to patients effectively. Among the various options, Intravenous administration provides rapid therapeutic action and is essential for patients experiencing severe attacks, ensuring immediate relief. Subcutaneous delivery is becoming increasingly popular due to its ease of use, allowing patients to self-administer medication at home, thereby enhancing treatment adherence and convenience. Oral administration also plays a significant role, particularly for long-term management, as it appeals to patients' preferences for non-invasive treatment methods.The interplay between these routes addresses diverse patient needs and scenarios, driving innovation and fostering growth in the market. With a growing population affected by hereditary angioedema and advancements in drug formulations, the Route of Administration segment stands out as a key focus area for pharmaceutical companies aiming to expand their offerings and improve patient outcomes. Furthermore, the increasing awareness of hereditary angioedema and ongoing Research and Development efforts are anticipated to bolster these routes, making safe and effective therapies more accessible to patients across the United States.

Hereditary Angioedema Therapeutics Market Distribution Channel Insights

The US Hereditary Angioedema Therapeutics Market is primarily segmented through various Distribution Channels, which play a crucial role in ensuring that patients have access to necessary treatments. Hospital Pharmacy is pivotal as it offers specialized medication management and immediate access to therapies for patients receiving treatment in clinical settings. Retail Pharmacy has a substantial presence, providing convenience and accessibility for patients who prefer to obtain their medications within their local communities, making it a favored option for chronic condition management.Meanwhile, Online Pharmacy is gaining significant traction due to the increasing preference for telehealth services and the convenience of home delivery, especially post-pandemic. The rise of digital health solutions has driven a notable shift towards online platforms, enabling patients to bypass traditional hurdles in accessing therapies. All these distribution channels are essential for meeting the diverse needs of patients, ultimately supporting the market growth by enhancing therapeutic reach and improving patient adherence to prescribed regimens in the US.

US Hereditary Angioedema Therapeutics Market Key Players and Competitive Insights:

The US Hereditary Angioedema Therapeutics Market has become increasingly competitive as pharmaceutical companies strive to address the unmet medical needs of patients suffering from this rare and potentially life-threatening condition. The market is characterized by a range of therapeutic options, including C1-esterase inhibitor therapies, bradykinin receptor antagonists, and other innovative treatments aimed at reducing the frequency and severity of angioedema attacks. The rise in awareness of hereditary angioedema, improved diagnostic techniques, and ongoing research and development efforts contribute to a dynamic landscape where companies are competing for market share and striving to deliver effective solutions that enhance patient outcomes. Regulatory advancements also play a critical role in shaping the competitive environment, facilitating the approval and commercialization of new therapeutics. AstraZeneca holds a notable presence in the US Hereditary Angioedema Therapeutics Market, leveraging its strong research and development capabilities to address this niche therapeutic area. The company's approach is supported by its robust pipeline and commitment to innovation, which enables it to explore novel therapeutic modalities. AstraZeneca's established distribution channels and collaborations with leading healthcare providers reinforce its market position. The company utilizes a patient-centered strategy, focusing on increasing awareness and providing comprehensive support to patients and healthcare professionals, thereby fostering brand loyalty and enhancing treatment adherence. Moreover, AstraZeneca's investment in clinical trials demonstrates its dedication to ensuring the efficacy and safety of its therapies, further solidifying its reputation in the industry.Takeda Pharmaceutical is another key player in the US Hereditary Angioedema Therapeutics Market, recognized for its comprehensive range of treatment options that cater to the needs of patients with this condition. The company's key products include C1-esterase inhibitors and bradykinin receptor antagonists, which have been developed to significantly reduce the frequency of angioedema attacks and improve quality of life. Takeda's commitment to research and development is highlighted by its ongoing investment in clinical trials and its focus on innovation within the hereditary angioedema therapeutic domain. Furthermore, Takeda's strategic mergers and acquisitions have bolstered its portfolio, enabling the company to enhance its market presence and expand its reach within the US region. By combining its operational strengths with a deep understanding of patient needs, Takeda aims to provide effective solutions while fortifying its position in the rapidly evolving landscape of hereditary angioedema therapeutics.

Key Companies in the US Hereditary Angioedema Therapeutics Market Include:

AstraZeneca

Takeda Pharmaceutical

Regeneron Pharmaceuticals

CSL Behring

Shire

Emergent BioSolutions

Ridgeback Biotherapeutics

ChanRx

Amgen

Ionis Pharmaceuticals

Sanofi

Pharming Group

Intellia Therapeutics

Biocryst Pharmaceuticals

Vertex Pharmaceuticals

US Hereditary Angioedema Therapeutics Market Industry Developments

The US Hereditary Angioedema Therapeutics Market has seen significant developments recently. In June 2023, CSL Behring announced progress in its gene therapy development for hereditary angioedema, showcasing advancements in reducing treatment frequency for patients while enhancing efficacy. Takeda Pharmaceutical reported elevated market performance due to the successful launch of its new therapies, which have gained traction among healthcare professionals and patients for their improved safety profiles. In terms of mergers and acquisitions, Emergent BioSolutions completed its acquisition of a small biotech firm focused on rare diseases, including hereditary angioedema, in July 2023. Furthermore, Biocryst Pharmaceuticals achieved a market valuation growth following its innovative product launches; this has solidified its presence in the American market, contributing to an overall market expansion. Over the past two to three years, the market has also seen heightened competition and increased investment in Research and Development as companies such as Amgen and Regeneron Pharmaceuticals emphasize novel therapeutics aimed at improving patient outcomes. Government support through funding for cutting-edge therapies has further stimulated market activity, promising a robust growth landscape for the industry moving forward.

US Hereditary Angioedema Therapeutics Market Segmentation Insights

Hereditary Angioedema Therapeutics Market Type Outlook

Type I

Type II

Hereditary Angioedema Therapeutics Market Drug Class Outlook

C1 Esterase Inhibitor

Selective Bradykinin B2 Receptor Antagonist

Kallikrein Inhibitor

Others

Hereditary Angioedema Therapeutics Market Treatment Outlook

Prophylaxis - Long-term Prophylaxis

Short-term Prophylaxis

On-demand

Hereditary Angioedema Therapeutics Market Route of Administration Outlook

Intravenous

Subcutaneous

Oral

Hereditary Angioedema Therapeutics Market Distribution Channel Outlook

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Report Scope:

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	1.43(USD Billion)
MARKET SIZE 2024	1.65(USD Billion)
MARKET SIZE 2035	9.13(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	16.827% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	AstraZeneca, Takeda Pharmaceutical, Regeneron Pharmaceuticals, CSL Behring, Shire, Emergent BioSolutions, Ridgeback Biotherapeutics, ChanRx, Amgen, Ionis Pharmaceuticals, Sanofi, Pharming Group, Intellia Therapeutics, Biocryst Pharmaceuticals, Vertex Pharmaceuticals
SEGMENTS COVERED	Type, Drug Class, Treatment, Route of Administration, Distribution Channel
KEY MARKET OPPORTUNITIES	Growing patient awareness programs, Advancements in gene therapy, Increased funding for research, Strategic partnerships and collaborations, Expanding telehealth services for management
KEY MARKET DYNAMICS	Increasing patient awareness, Rising treatment options, Strong pipeline developments, Regulatory support initiatives, High healthcare expenditure
COUNTRIES COVERED	US